Antitrust Review Reshapes Large-Cap Deal Planning
Antitrust policy is drawing fresh attention from market participants as merger review, market definition and remedies evolves.
Large transactions face longer reviews and more demanding remedies. Companies are building antitrust risk into deal timelines and valuation, particularly in technology and healthcare.
Deal spreads may remain wider until the review process becomes more predictable.
The main risk is prolonged reviews and litigation risk. Investors should watch merger filings, regulatory challenges and settlement terms in the sessions ahead.
This article is provided for information and educational purposes only and does not constitute investment advice. Market conditions can change, and past performance is not a guarantee of future results.